Literature DB >> 33490001

Hemostatic Testing in Critically Ill Infants and Children.

Alison B Nair1, Robert I Parker2.   

Abstract

Children with critical illness frequently manifest imbalances in hemostasis with risk of consequent bleeding or pathologic thrombosis. Traditionally, plasma-based tests measuring clot formation by time to fibrin clot generation have been the "gold standard" in hemostasis testing. However, these tests are not sensitive to abnormalities in fibrinolysis or in conditions of enhanced clot formation that may lead to thrombosis. Additionally, they do not measure the critical roles played by platelets and endothelial cells. An added factor in the evaluation of these plasma-based tests is that in infants and young children plasma levels of many procoagulant and anticoagulant proteins are lower than in older children and adults resulting in prolonged clot generation times in spite of maintaining a normal hemostatic "balance." Consequently, newer assays directly measuring thrombin generation in plasma and others assessing the stages hemostasis including clot initiation, propagation, and fibrinolysis in whole blood by viscoelastic methods are now available and may allow for a global measurement of the hemostatic system. In this manuscript, we will review the processes by which clots are formed and by which hemostasis is regulated, and the rationale and limitations for the more commonly utilized tests. We will also discuss selected newer tests available for the assessment of hemostasis, their "pros" and "cons," and how they compare to the traditional tests of coagulation in the assessment and management of critically ill children.
Copyright © 2021 Nair and Parker.

Entities:  

Keywords:  coagulopathy; developmental hemostasis; diagnosis; pediatric; viscoelastic

Year:  2021        PMID: 33490001      PMCID: PMC7820389          DOI: 10.3389/fped.2020.606643

Source DB:  PubMed          Journal:  Front Pediatr        ISSN: 2296-2360            Impact factor:   3.418


  133 in total

Review 1.  Platelets and thrombin generation.

Authors:  Dougald M Monroe; Maureane Hoffman; Harold R Roberts
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-09-01       Impact factor: 8.311

Review 2.  Methods for testing platelet function for transfusion medicine.

Authors:  S Panzer; P Jilma
Journal:  Vox Sang       Date:  2011-03-29       Impact factor: 2.144

Review 3.  Platelet GPIb-V-IX complex.

Authors:  K J Clemetson
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

Review 4.  The roles of protein C and thrombomodulin in the regulation of blood coagulation.

Authors:  C T Esmon
Journal:  J Biol Chem       Date:  1989-03-25       Impact factor: 5.157

5.  Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor.

Authors:  R J Baugh; G J Broze; S Krishnaswamy
Journal:  J Biol Chem       Date:  1998-02-20       Impact factor: 5.157

6.  Should we abandon the APTT for monitoring unfractionated heparin?

Authors:  D R J Arachchillage; F Kamani; S Deplano; W Banya; M Laffan
Journal:  Thromb Res       Date:  2017-07-06       Impact factor: 3.944

Review 7.  Coagulopathy of Trauma.

Authors:  Mitchell J Cohen; S Ariane Christie
Journal:  Crit Care Clin       Date:  2017-01       Impact factor: 3.598

8.  Particle volume changes associated with light transmittance changes in the platelet aggregometer: dependence upon aggregating agent and effectiveness of stimulus.

Authors:  N T Thompson; M C Scrutton; R B Wallis
Journal:  Thromb Res       Date:  1986-03-01       Impact factor: 3.944

9.  Abnormalities in fibrinolysis at the time of admission are associated with deep vein thrombosis, mortality, and disability in a pediatric trauma population.

Authors:  Christine M Leeper; Matthew D Neal; Christine McKenna; Jason L Sperry; Barbara A Gaines
Journal:  J Trauma Acute Care Surg       Date:  2017-01       Impact factor: 3.313

Review 10.  The Emerging Role of NETs in Venous Thrombosis and Immunothrombosis.

Authors:  Andrew S Kimball; Andrea T Obi; Jose A Diaz; Peter K Henke
Journal:  Front Immunol       Date:  2016-06-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.